The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.
 
Jacob Drobnyk Soumerai
Consulting or Advisory Role - Abbvie; AstraZeneca; Verastem
Research Funding - BeiGene; BostonGene; Genentech/Roche; TG Therapeutics
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; Celgene; Janssen Oncology; Loxo; PER; Pharmacyclics; Prime Oncology; Sunesis Pharmaceuticals; TG Therapeutics; Verastem; Verastem
Research Funding - Abbvie/Genentech; Adaptive Biotechnologies; BeiGene; Genentech; LOXO; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics; Verastem
Travel, Accommodations, Expenses - Pfizer; TG Therapeutics
Other Relationship - Celgene; TG Therapeutics
 
Jason Carter
Employment - Syneos Health (I)
Travel, Accommodations, Expenses - MEI Pharma
 
Ahmet Dogan
Consulting or Advisory Role - Abbvie; EUSA Pharma; Roche; Seagen; Takeda
Research Funding - Roche/Genentech
 
Ephraim Hochberg
No Relationships to Disclose
 
Jeffrey A. Barnes
No Relationships to Disclose
 
Audrey M. Hamilton
No Relationships to Disclose
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Alimera Sciences; Alimera Sciences; Bayer; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Merck; MorphoSys; Novartis; Verastem
Research Funding - AI Therapeutics (Inst); Celgene (Inst); Seagen (Inst)
 
Connie Lee Batlevi
Honoraria - Dava Oncology
Consulting or Advisory Role - Celgene; Gerson Lehrman Group; Juno Therapeutics; Kite, a Gilead company; Lifesci Capital; Lifesci Capital; Seagen
Research Funding - Bayer (Inst); Epizyme; Janssen Biotech; Novartis; Xynomic Pharma
 
Erel Joffe
Consulting or Advisory Role - AstraZeneca
 
Matthew J. Matasar
Stock and Other Ownership Interests - Merck
Honoraria - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Teva
Research Funding - Bayer; Genentech; GlaxoSmithKline; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen
 
Ariela Noy
Consulting or Advisory Role - MorphoSys
Speakers' Bureau - Prime Oncology
Research Funding - Pharmacyclics; Rafael Pharmaceuticals
Travel, Accommodations, Expenses - Janssen Oncology; Pharmacyclics
 
Colette Ngozi Owens
No Relationships to Disclose
 
Maria Lia Palomba
Stock and Other Ownership Interests - Seres Therapeutics (I)
Honoraria - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Merck; Merck (I); Novartis (I); Pharmacyclics; Seres Therapeutics (I); Therakos (I)
Consulting or Advisory Role - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Kite, a Gilead company; Merck; Merck (I); Novartis; Novartis (I); Seres Therapeutics (I); Therakos (I)
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)
 
Tak Takvorian
No Relationships to Disclose
 
Kelsey Flaherty
No Relationships to Disclose
 
Lauren Ramos
No Relationships to Disclose
 
Lindsey Elizabeth Roeker
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I)
Honoraria - Projects in Knowledge; Vaniam Group
Travel, Accommodations, Expenses - Vaniam Group
 
Omar Ibrahim Abdel-Wahab
Consulting or Advisory Role - Envisagenics; Foundation Medicine; H3 Biomedicine
Research Funding - H3 Biomedicine
 
Andrew David Zelenetz
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Clinical Care Options; NCCN; Oncology Information Group; PER
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Cancer Support Community; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; Karyopharm Therapeutics; Medscape; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Prime Education; TRM Oncology; Vaniam Group; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma